Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

DSM, which created and manufactures Dyneema Purity, the world's strongest Medical grade fiber, today announced agreements with Biomedical Structures, Cortland Company and Secant Medical. These companies' experience in processing Dyneema Purity fiber in biomedical textile structures offers medical device companies the ability to use various constructions of Dyneema Purity, including the recently launched Dyneema Purity BLUE, in commercial medical devices.

9 Jun 2010

BD to sell certain assets of Medical segment

BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it has signed agreements to sell certain assets of its BD Medical segment, including the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms of the Medical Surgical Systems unit.

From BD (Becton, Dickinson and Company) 8 Jun 2010

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

8 Jun 2010

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today reported preliminary outcomes and trends from the ongoing Phase III pivotal study of Generex Oral-lyn, the Company's proprietary oral insulin spray product.

7 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Leonardo Biosystems receives $2.5M grant to accelerate commercialization of new technologies

Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.

7 Jun 2010

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.

7 Jun 2010

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc. today announced that it has entered into an expanded relationship with Novartis Pharma AG pursuant to which Novartis has cancelled the Company's Convertible Promissory Note. The Note was originally issued to Novartis on December 1, 2004 in connection with the Research Collaboration and Option License Agreement between the parties of that date and was originally due December 1, 2009. Previously, Novartis had agreed to extend the maturity date to June 4, 2010.

4 Jun 2010

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Particle Sciences has expanded its Bioanalytic Service's offerings to include Dried Blood Spot LC/MS/MS analysis (DBS). DBS is a growing area of interest because of its advantages in sample collection, stability, and simplified storage requirements. By using DBS, sample collection and processing is greatly simplified resulting in decreased costs, increased safety and greater comfort for test subjects.

4 Jun 2010

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Cure Alzheimer's Fund recently awarded the University of Texas Health Science Center at Houston and the University of Houston a $150,000 grant to fund innovative research on Alzheimer's disease, which currently affects 5.3 million Americans and their families and is the most common cause of dementia in the elderly.

3 Jun 2010

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

BD Diagnostics, a segment of BD, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS Assay for Group B Streptococcus on the BD MAX System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads for maximum lab efficiency and flexibility.

From BD (Becton, Dickinson and Company) 3 Jun 2010

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

US Oncology, Inc., the nation's leading integrated oncology company, today announced its new iKnowMed™ Technology Platform to support community oncologists nationwide. This new platform enhances cancer care quality and practice efficiency through integrated, oncology-specific technologies that enable community oncologists to solve challenges in the areas of care delivery, drug management, and revenue cycle management.

2 Jun 2010

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.

2 Jun 2010

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.

29 May 2010

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor David Zaharoff has been awarded a Transition Career Development Award by the National Cancer Institute to further his research on Interleukin-12, a powerful cytokine that shows great promise for therapeutic treatment of numerous types of cancer.

28 May 2010

Emisphere Technologies announces further extension of Convertible Promissory Note maturity date

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere's Convertible Promissory Note to June 4, 2010.

27 May 2010

Drug Delivery News and Research

Further Reading

Endo, Penwest announce settlement of OPANA ER litigation with Impax

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

BD to sell certain assets of Medical segment

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Leonardo Biosystems receives $2.5M grant to accelerate commercialization of new technologies

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

Biomedical engineering professor receives Transition Career Development Award

Emisphere Technologies announces further extension of Convertible Promissory Note maturity date

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News